Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | DBH | P09172 | 1/20 | 0.46 |
| ▸ | SLC29A1 | Q99808 | 7/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | XDH | P47989 | 1/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7812404 | 0.81 | PARN (0.54) | — | |
| SCHEMBL7977499 | 0.80 | CYP11B1 (0.48) | LMNAMEN1KMT2ANR1I2 | |
| SCHEMBL7120147 | 0.75 | DAO (0.40) | KMT2ACYP19A1ADORA2ANR1I2 | |
| SCHEMBL30072053 | 0.72 | LMNA (0.56) | LMNAMEN1KMT2ADBHSLC29A1 | |
| SCHEMBL30804827 | 0.70 | ADORA2A (0.40) | ADORA2A | |
| SCHEMBL20561820 | 0.69 | LMNA (0.71) | LMNA | |
| Hydrochloric Acid SCHEMBL7813292 | 0.69 | DHFR (0.56) | LMNAMEN1KMT2ADBHSLC29A1 | |
| SCHEMBL28017562 | 0.69 | MEN1 (0.55) | LMNAMEN1KMT2ADBHSLC29A1 | |
| SCHEMBL29601391 | 0.68 | MEN1 (0.46) | LMNAMEN1KMT2ADBHSLC29A1 | |
| SCHEMBL7117268 | 0.68 | LMNA (0.46) | LMNAMEN1KMT2ADBHCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030186978-A1 | Novel telomerase inhibitors | PHARMACIA ITALIA, SPA (IT) | 2003-10-02 | — | — | US | claimed |
| US-20030186978-A1 | Novel telomerase inhibitors | PHARMACIA ITALIA, SPA (IT) | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186978-A1 | Novel telomerase inhibitors | TERT, TERF2IP, TERF2 | LMNA 1848/4885MEN1 1870/4885KMT2A 1026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.